DBV Technologies SA

DBV Technologies to Participate in Upcoming Investor Conference

06 июн 2023 16:00:00 Источник Nasdaq GlobeNewswire

DBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial Data Evaluating Viaskin™ Peanut in Toddlers

10 май 2023 16:30:00 Источник Nasdaq GlobeNewswire

DBV Technologies to Participate in Upcoming Investor Conference

09 май 2023 15:30:00 Источник Nasdaq GlobeNewswire

DBV Technologies Reports First Quarter 2023 Financial Results

04 май 2023 15:30:00 Источник Nasdaq GlobeNewswire

DBV Technologies Outlines Regulatory Path for Viaskin Peanut in Children 1 – 3 Years After Receiving Pre-BLA Responses from FDA

19 апр 2023 16:09:21 Источник Nasdaq GlobeNewswire

DBV Technologies Announces Results of its 2023 Ordinary and Extraordinary General Meeting

12 апр 2023 15:30:00 Источник Nasdaq GlobeNewswire

Ordinary and Extraordinary General Meeting of April 12, 2023

24 мар 2023 15:30:00 Источник Nasdaq GlobeNewswire

DBV Technologies Update

13 мар 2023 00:30:00 Источник Nasdaq GlobeNewswire

DBV Technologies Announces First Patient Screened in VITESSE Phase 3 Clinical Trial in Peanut-Allergic Children 4 – 7 Years Old

07 мар 2023 15:30:00 Источник Nasdaq GlobeNewswire

DBV Technologies announces filing of 2022 Annual Report on Form 10-K and 2022 Universal Registration Document

02 мар 2023 16:30:00 Источник Nasdaq GlobeNewswire

DBV Technologies Reports Full Year 2022 Financial Results and Business Update

02 мар 2023 15:30:00 Источник Nasdaq GlobeNewswire

DBV Technologies to Participate in Upcoming AAAAI 2023 Congress

21 фев 2023 15:30:00 Источник Nasdaq GlobeNewswire

DBV Technologies to Participate in Upcoming Investor Conference

10 фев 2023 15:30:00 Источник Nasdaq GlobeNewswire

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

23 янв 2023 15:30:00 Источник Nasdaq GlobeNewswire

Monthly information regarding the total number of voting rights and total number of shares of the Company as of December 31, 2022

04 янв 2023 15:30:00 Источник Nasdaq GlobeNewswire

DBV Technologies Announces FDA Has Lifted Partial Clinical Hold on VITESSE Phase 3 Pivotal Trial  

23 дек 2022 00:30:00 Источник Nasdaq GlobeNewswire

Monthly information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2022

08 дек 2022 15:30:00 Источник Nasdaq GlobeNewswire

DBV Technologies to Participate in Upcoming Investor Conference

22 ноя 2022 15:30:00 Источник Nasdaq GlobeNewswire

DBV Technologies to Highlight New Clinical Data at ACAAI 2022

09 ноя 2022 00:30:00 Источник Nasdaq GlobeNewswire

DBV Technologies Reports Third Quarter Financial Results and Business Update

03 ноя 2022 15:30:00 Источник Nasdaq GlobeNewswire